Is anticoagulant therapy necessary after hospitalization with COVID-19 pneumonia?

The coronavirus disease 2019 (COVID-19) pandemic is associated with high virulence, mortality and healthcare burden around the world. One of its features is procoagulant activity, which leads to a high incidence of thromboembolic events in the lungs and other organs. Therefore, from the very onset o...

Descripció completa

Dades bibliogràfiques

Autors principals:	P. A. Davtyan, R. M. Gumerov, Sh. Z. Zagidullin, A. V. Samorodov, B. Cai, N. Sh. Zagidullin
Format:	Artigo
Idioma:	Russo
Publicat:	«FIRMA «SILICEA» LLC 2022-02-01
Col·lecció:	Российский кардиологический журнал
Matèries:	coronavirus disease 2019 covid-19 sars-cov-2 cardiovascular diseases anticoagulants long covid-19
Accés en línia:	https://russjcardiol.elpub.ru/jour/article/view/4652
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!